Shuttle Pharmaceuticals (NASDAQ:SHPH) Major Shareholder Buys $21,818.65 in Stock

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt acquired 6,755 shares of the company’s stock in a transaction dated Tuesday, June 30th. The stock was acquired at an average cost of $3.23 per share, with a total value of $21,818.65. Following the transaction, the insider directly owned 78,597 shares of the company’s stock, valued at approximately $253,868.31. This represents a 9.40% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Monday, June 29th, Financial Lp Hrt bought 25,836 shares of Shuttle Pharmaceuticals stock. The shares were bought at an average price of $3.44 per share, for a total transaction of $88,875.84.

Shuttle Pharmaceuticals Stock Performance

Shares of SHPH stock traded up $0.15 on Wednesday, hitting $3.40. The stock had a trading volume of 169,219 shares, compared to its average volume of 2,351,062. The stock’s 50 day moving average is $5.93 and its 200-day moving average is $10.74. The firm has a market capitalization of $2.18 million, a price-to-earnings ratio of -0.07 and a beta of 0.29. Shuttle Pharmaceuticals Holdings, Inc. has a 52-week low of $2.90 and a 52-week high of $55.90.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $0.60 EPS for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research note on Tuesday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in SHPH. Connective Capital Management LLC acquired a new position in Shuttle Pharmaceuticals during the 3rd quarter worth $357,000. Ikarian Capital LLC bought a new position in shares of Shuttle Pharmaceuticals during the fourth quarter worth about $124,000. Boothbay Fund Management LLC acquired a new position in Shuttle Pharmaceuticals in the fourth quarter worth about $37,000. Finally, Geode Capital Management LLC acquired a new position in Shuttle Pharmaceuticals in the fourth quarter worth about $26,000. 4.58% of the stock is currently owned by institutional investors.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .